Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Johnson & Johnson : Says Discounts Cut the Prices for Its Drugs, Though Revenue Rose

share with twitter share with LinkedIn share with facebook
share via e-mail
03/09/2018 | 12:39am CEST

By Jonathan D. Rockoff

Johnson & Johnson said Thursday the average price paid for its medicines in the U.S. fell by 4.6% last year due to the company's discounts, and the company's pharmaceuticals chief expects the pricing pressures on drugmakers will continue this year.

J&J, one of the biggest sellers of prescription drugs in the U.S., said it raised the list prices for its medicines by an average 8.1%, but they wound up as a whole costing far less because the manufacturer handed out $15 billion in discounts and rebates.

"That shows the level of competition that exists in the U.S. market," Joaquin Duato, who heads J&J's pharmaceuticals business, said in an interview.

Overall J&J's U.S. pharmaceutical sales still did well last year, rising 6.7% to $21.5 billion. Mr. Duato said that the increase stemmed from higher volume, not prices.

Several drugmakers provide aggregate pricing data each year partly to blunt public criticism of rising drug prices and shift focus to health-care companies like drug-benefit managers that can profit from the price increases as well as from raising the copays patients pay for medicines.

Merck & Co. said last month that the prices of its drugs and vaccines fell 1.9% in the U.S. last year after discounts and rebates.

Mr. Duato attributed the pricing squeeze to three factors that he expects to keep the drug industry's prices after discounts "flat" this year.

Health plans and drug-benefit managers are "more aggressive" restricting access to expensive drugs, and drug companies are required to provide discounts to growing numbers of patients in Medicaid and hospitals in a drug-discount program known as 340(b), Mr. Duato said.

Lower-priced competition is also starting to have an impact on the pricing of biotechnology drugs, Mr. Duato said, as rivals start launching so-called biosimilar copies.

J&J's aggregate drug pricing last year reflected the impact of such competition for rheumatoid-arthritis treatment Remicade, which has been the company's top-selling product but began facing competition from a copy sold by Pfizer Inc. in late 2016.

Remicade's U.S. sales fell $317 million to $4.5 billion last year.

Remicade competition was a "big factor" in J&J's average net price drop last year "but it wasn't the only factor," Mr. Duato said. The average price for J&J's prescription drugs after discounts was negative in 2017 excluding Remicade, he said.

Some analysts had expected a bigger drop in U.S. Remicade sales than what J&J experienced, but said J&J had managed to hold on to much of its Remicade business in the U.S. by offering deep discounts and other perks to limit switching to the rival drug.

Pfizer has sued J&J alleging it thwarted the "biosimilar" competition through "exclusionary contracts" with health insurers, hospitals and clinics. J&J has said the lawsuit lacks merit.

Write to Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
09/22HIGH SCHOOL FOOTBALL : West Rowan-Concord box
09/22J&J UNIT : Esketamine Study Didn't Show Statistical Significance for Primary End..
09/22JOHNSON & JOHNSON : 'Healthy Babies Are Worth the Wait' program to be held on We..
09/22JOHNSON & JOHNSON : Janssen Announces Results of Esketamine Nasal Spray Phase 3 ..
09/21JOHNSON & JOHNSON : J&J Unit Agrees To Sell Sterilization Unit for $2.7 Billion
09/21JOHNSON & JOHNSON : to Host Investor Conference Call on Third-Quarter Results
09/21JOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. FDA Seeking App..
09/21JOHNSON & JOHNSON : Vision Showcases Latest Clinical Data and Eye Care Solutions..
09/21Janssen launches first long-acting treatment for schizophrenia
09/21Janssen launches first long-acting treatment for schizophrenia
More news
News from SeekingAlpha
09/23The 3 Essential Investing Lessons Of The Financial Crisis 
09/22STOCKS TO WATCH : Calling Up Animal Spirits 
09/21Sutro Biopharma Prepares Terms For $75 Million U.S. IPO 
09/21Buy This Stock If You Are Afraid Of An Imminent Bear Market 
Financials ($)
Sales 2018 81 257 M
EBIT 2018 24 952 M
Net income 2018 16 036 M
Debt 2018 11 280 M
Yield 2018 2,50%
P/E ratio 2018 21,10
P/E ratio 2019 18,25
EV / Sales 2018 4,86x
EV / Sales 2019 4,62x
Capitalization 383 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 144 $
Spread / Average Target 0,43%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092
AMGEN17.94%132 756